Status: Recruiting

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.

Participants needed: 2,500

Trial details

Age: 18+Biological sex: AllType: ObservationalSponsor: Convergent Genomics, Inc.Updated: Jun 29, 2026Locations: 23

Eligibility criteria

Male or female ≥ 18 years of age who are scheduled for transurethral resection o... [+10]

Clinical, symptomatic urinary tract infection at time of initial urine collectio... [+1]

Status: Recruiting

Urine Methylation Markers in UTUC

This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine samples will be de-identified and sent to Pangea Laboratory LLC for analysis. The results of this test will be compared to the traditional tests in upper tract urothelial cancer, such as cells in the urine and tissue biopsy.

Participants needed: 50

Trial details

Age: 18+Biological sex: AllType: InterventionalSponsor: Duke UniversityUpdated: Jun 1, 2026Locations: 1

Eligibility criteria

>=18 years [+1]

Patients who do not understand and/or are unwilling to sign a written informed c...

Status: Recruiting

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of a combination chemotherapy treatment for patients with favorable papillary high-grade upper tract urothelial carcinoma (UTUC). The study focuses on sequential administration of two drugs, gemcitabine and Jelmyto (a gel-based form of mitomycin), to potentially preserve kidney function and avoid nephroureterectomy (kidney removal), which is the current standard of care for participants with non-endoscopically resectable tumors.

Participants needed: 28

Trial details

Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Rutgers, The State University of New JerseyUpdated: May 6, 2026Locations: 1

Eligibility criteria

Patient has signed Informed Consent Form and is willing and able to comply with... [+6]

At least 12 months since the last menses, or [+3]

Status: Recruiting

Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients

To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery

Participants needed: 25

Trial details

Age: 20+Biological sex: AllType: InterventionalSponsor: National Taiwan University HospitalUpdated: May 23, 2025Locations: 1

Eligibility criteria

Age 20 years or more [+5]

Synchronous bladder cancer [+12]

Status: Recruiting

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

This study aims to prospectively observe whether certain alterations in some genes related to the DNA repair mechanism are related to better response to platinum-based chemotherapy used to treat metastatic bladder or urothelial cancers.

Participants needed: 135

Trial details

Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSUpdated: Feb 11, 2025Locations: 1

Eligibility criteria

Informed consent obtained before any study-specific procedures. Patients must be... [+8]

Previous treatment for metastatic or locally advanced disease. [+22]

Status: Recruiting

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients

Participants needed: 300

Trial details

Age: 18+Biological sex: AllType: ObservationalSponsor: Chinese University of Hong KongUpdated: Jan 23, 2024Locations: 1

Eligibility criteria

Male patients > 18 years old [+2]